AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 192 min read$MANE

Veradermics Stock Rises 7% After Positive Phase 3 Hair Loss Trial Results

Veradermics (MANE) stock rose 6.98% to $116.42 after positive Phase 3 trial results for its hair loss treatment VDPHL01, meeting all endpoints with statistical significance. The trial involved 536 males with mild-to-moderate hair loss, showing significant hair count increases compared to placebo. The company expects further data later this year and in 2027.

Original reporting
rttnews.com
Published Oct 19, 2026, 3:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 6:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Veradermics Stock Rises 7% After Positive Phase 3 Hair Loss Trial Results — source image
Source · rttnews.com
Decision brief

The 30-second read

$MANEBullishHigh
01

Why it matters

The announcement triggered a near‑7% intraday gain, reflecting market optimism about a potential new therapy.

02

Market read

The trial results constitute a primary catalyst for MANE, offering a clear short‑term trading opportunity.

03

What to watch

Potential competition from existing minoxidil products and the need for FDA filing timelines.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Veradermics (MANE) is a biotech focused on hair‑loss treatments; the Phase 3 study enrolled 536 men and met all endpoints.

Company-level read

Ticker impact

$MANEBullishHigh confidence
Context

Veradermics reported positive Phase 3 topline data for its oral minoxidil product, driving a 6.98% price jump.

Expected impact

upward pressure as the market absorbs the positive efficacy data.

Evidence & confidence

Phase 3 data is material for a biotech; the stock already rose ~7% on the news, indicating strong demand.

Market effects

Sector

Positive hair‑loss trial data may boost sentiment toward other dermatology and hair‑loss biotech firms.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Modest global relevance, primarily affecting biotech and specialty pharma investors.

Counterpoint

What could challenge this read

If the data does not translate into regulatory approval or commercial uptake, the rally could be short‑lived.

Key entities

  • company
    Veradermics, Incorporated

    Biotech developer of oral minoxidil formulation VDPHL01.

Read at source← All news

StoryVeradermics reports Phase 3 trial success for oral hair‑loss drug VDPHL01

Also covered by

1 outlet

Related articles

OCT 19
MedAI 9/10

Veradermics’ stock up on male hair loss trial success

Veradermics' stock rose 6% after its Phase III trial for male hair loss drug VDPHL01 met all endpoints, showing significant hair growth vs. placebo. The drug was well-tolerated, with 78.8% and 85.0% of patients reporting improvement in once-daily and twice-daily arms, respectively. Veradermics aims for FDA approval, potentially becoming the first oral pill for pattern hair loss in 30 years.

finance.yahoo.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment

Veradermics (MANE) shares rose 10% after its oral hair-loss pill, VDPHL01, met all primary and secondary goals in a second Phase 3 trial. The pill increased hair count significantly compared to placebo with no serious cardiac events. The company expects 12-month safety data later this year. Veradermics has sufficient cash to potentially reach a launch, according to management.

finance.yahoo.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results

Veradermics (NYSE:MANE) reported positive results from its Phase III trial for VDPHL01 in male pattern hair loss, meeting all endpoints. The trial showed strong growth with mild to moderate adverse events. The company plans to release extension data from Study 302 later this year and expects results from a female pattern hair loss study in 2027. Veradermics has $820 million in cash and is evaluating regulatory filing strategies.

finance.yahoo.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics posts positive Phase 3 '304' topline: VDPHL01 raises hair count up to 36.4 hairs/cm², no treatment‑related SAEs

Veradermics (MANE) reported positive Phase 3 results for VDPHL01, showing significant hair growth and a favorable safety profile. The study met all endpoints, with hair count increases of 28.6 (QD) and 36.4 (BID) hairs/cm² vs. 6.6 for placebo. Patient-reported improvements were 78.8% (QD) and 85.0% (BID) vs. 35.3% for placebo. No treatment-related serious adverse events were reported.

tradingview.com1 min
OCT 19
$MANEHighAI 8/10

Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss

Veradermics, Inc (MANE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with h

SEC EDGAR 8-K2 min